-
Tytuł:
-
Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis.
-
Autorzy:
-
Zizza A; Institute of Clinical Physiology, National Research Council, 73100, Lecce, Italy.
Banchelli F; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41100, Modena, Italy.
Guido M; Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, University of Salento, Via Prov.Le Lecce-Monteroni, 165, 73100, Lecce, Italy. .; Inter-University Centre of Research on Influenza and Other Transmissible Infections (CIRI-IT), University of Genoa, 16100, Genoa, Italy. .
Marotta C; Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90100, Palermo, Italy.; Medical Direction, IRCCS Neuromed, 86170, Pozzilli, IS, Italy.
Di Gennaro F; Department of Infectious Diseases, University of Bari 'Aldo Moro', 70124, Bari, Italy.
Mazzucco W; Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90100, Palermo, Italy.; Clinical Epidemiology and Cancer Registry Unit, COVID-19 Sicilian Regional Reference Lab, Palermo University Hospital (AOUP) 'P. Giaccone', 90100, Palermo, Italy.; Division of Biostatistics and Epidemiology, Department of Pediatric, Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Pistotti V; Indipendent Researcher, Milan, Italy.
D'Amico R; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41100, Modena, Italy.
-
Źródło:
-
Scientific reports [Sci Rep] 2021 Mar 02; Vol. 11 (1), pp. 4954. Date of Electronic Publication: 2021 Mar 02.
-
Typ publikacji:
-
Journal Article; Meta-Analysis; Systematic Review
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: London : Nature Publishing Group, copyright 2011-
-
MeSH Terms:
-
Patient Safety*
CD4-Positive T-Lymphocytes/*immunology
HIV Infections/*immunology
Papillomavirus Infections/*prevention & control
Papillomavirus Vaccines/*immunology
Adolescent ; Adult ; Antibodies, Viral ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/virology ; Female ; Humans ; Male ; Papillomavirus Infections/virology ; Papillomavirus Vaccines/adverse effects ; Public Health ; Randomized Controlled Trials as Topic ; Risk ; Treatment Outcome ; Viral Load ; Virus Shedding ; Young Adult
-
References:
-
Virology. 2013 Nov;446(1-2):378-88. (PMID: 24074602)
J Infect Dis. 2013 Feb 1;207(3):402-10. (PMID: 23175769)
Sex Transm Dis. 2011 Oct;38(10):932-40. (PMID: 21934568)
Int J Cancer. 2012 Nov 15;131(10):2349-59. (PMID: 22323075)
AIDS Patient Care STDS. 2014 Aug;28(8):397-410. (PMID: 25029589)
Expert Rev Anti Infect Ther. 2017 Nov;15(11):987-999. (PMID: 29027811)
Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. (PMID: 24229716)
Public Health. 2011 Jul;125(7):464-75. (PMID: 21722930)
J Clin Oncol. 2018 Jan 1;36(1):68-75. (PMID: 29140774)
J Infect Dis. 2018 Jan 4;217(2):208-212. (PMID: 29136168)
J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10. (PMID: 10995805)
J Autoimmun. 2017 Jun;80:10-27. (PMID: 28381345)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):. (PMID: 31755549)
Int J STD AIDS. 2019 Oct;30(11):1105-1115. (PMID: 31551002)
Clin Infect Dis. 2018 Oct 15;67(9):1339-1346. (PMID: 29659751)
Open Med. 2009;3(3):e123-30. (PMID: 21603045)
J Acquir Immune Defic Syndr. 2010 Oct;55(2):197-204. (PMID: 20574412)
N Engl J Med. 2020 Oct 1;383(14):1340-1348. (PMID: 32997908)
Vaccine. 2013 Nov 19;31(48):5745-53. (PMID: 24091311)
BMC Infect Dis. 2016 Aug 22;16(1):440. (PMID: 27549219)
Pediatrics. 2019 Feb;143(2):. (PMID: 30670582)
Wkly Epidemiol Rec. ;92(19):241-68. (PMID: 28530369)
J Infect Dis. 2019 Aug 30;220(7):1141-1146. (PMID: 31165164)
Curr Pharm Des. 2020;26(3):343-357. (PMID: 32048956)
AIDS Res Ther. 2017 Jul 18;14(1):34. (PMID: 28720147)
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. (PMID: 31415491)
AIDS. 2018 Mar 27;32(6):795-808. (PMID: 29369827)
Vaccine. 2012 Nov 20;30 Suppl 5:F168-74. (PMID: 23199960)
Int J STD AIDS. 2014 Mar;25(3):163-77. (PMID: 24216030)
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441. (PMID: 23189750)
Cochrane Database Syst Rev. 2018 May 09;5:CD009069. (PMID: 29740819)
-
Substance Nomenclature:
-
0 (Antibodies, Viral)
0 (Papillomavirus Vaccines)
-
Entry Date(s):
-
Date Created: 20210303 Date Completed: 20210316 Latest Revision: 20210316
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7925667
-
DOI:
-
10.1038/s41598-021-83727-7
-
PMID:
-
33654181
-
The prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the placebo group (MD = 4333.3, 95% CI 2701.4; 5965.1 GMT EL.U./ml for HPV type 16 and MD = 1408.8, 95% CI 414.8; 2394.7 GMT EL.U./ml for HPV type 18). There were also no differences in terms of severe adverse events (RR = 0.6, 95% CI 0.2; 1.6) and no severe adverse events (RR = 0.6, 95% CI 0.9; 1.2) between vaccine and placebo groups. Secondary outcomes, such as CD4 + T-cell count and HIV viral load, did not differ between groups (MD = 14.8, 95% CI - 35.1; 64.6 cells/µl and MD = 0.0, 95% CI - 0.3; 0.3 log10 RNA copies/ml, respectively). Information on the remaining outcomes was scarce and that did not allow us to combine the data. The results support the use of the HPV vaccine in HIV-infected patients and highlight the need of further RCTs assessing the effectiveness of the HPV vaccine on infections and neoplasms.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.